ClinicalTrials.gg
RecruitingNCT05208749SONARUpdated Jul 3, 2024

ShOckwave ballooN or Atherectomy With Rotablation in Calcified Coronary Artery Lesions, the SONAR Trial

An interventional study of Rotablation of shockwave in Calcified Atheroma and Coronary Artery Disease, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Universitaire Ziekenhuizen KU Leuven.

Started
2022
the only one that year
No phase
3 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, this one is the only one that started in 2022, is one of 3 with no phase, and was the 8th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

Percutaneous coronary interventions (PCI) is intended to relieve myocardial ischemia by improving blood flow in the epicardial coronary arteries. However, the efficacy of PCI may be compromised by incidental microvascular obstruction and peri-procedural myocardial infarction (PPMI), which occurs in about 10-15% of cases and is associated with increased rates of major adverse cardiovascular events (MACE). The mechanism of PPMI is thought to be related to side branch occlusion, coronary artery dissection and acute microvascular damage caused by embolization of plaque debris during the PCI and is more frequently seen in calcified coronary artery disease. Calcium modification by rotational atherectomy (RA) results in peri-procedural myocardial infarction in 24% of cases and myocardial injury in 70% of cases. The Shockwave coronary intravascular lithotripsy (IVL) balloon catheter emits sonic pressure waves in a circumferential field causing the selective fracture of calcium, altering vessel compliance and permitting further expansion of the vessel wall. This provides a potentially safer alternative to other calcium-modifying devices since there is a low risk of dissection and perforation. It is also proposed that this IVL device reduces the risk of atheromatous embolization, which would reduce the risk of PPMI and microvascular dysfunction. The SONAR Trial is a pilot study measuring peri-procedural myocardial injury, PPMI and microvascular dysfunction in patients (with calcified coronary artery lesions not responding to usual balloon dilatation) randomized to RA or Shockwave IVL. The primary outcome is peri-procedural myocardial infarction. Secondary outcomes include peri-procedural myocardial injury, acute microvascular dysfunction, procedural success, and procedural costs.

Read the detailed description

In this multicentre, prospective, randomized-controlled open label pilot study the investigators will measure rates of peri-procedural myocardial infarction and changes in microvascular function after PCI in 170 patients (85 per arm) treated with Shockwave intravascular lithotripsy (IVL) versus RA. Patients with moderately and/or severely calcified coronary lesions, which are equally suitable for IVL and RA and do not dilate fully (100%) with an appropriately sized non-compliant balloon at 16 atmospheres, will be recruited. The calcified lesion must be suitable for both IVL and RA and the operator believes that either IVL or RA could be used. The primary outcome will be difference in the rate of peri-procedural myocardial infarction (Type 4a of the universal Definition of Myocardial Infarction). Peri-procedural myocardial injury and infarction will be defined by an increase in high-sensitivity Troponin T according to the Fourth Universal Definition of Myocardial Infarction,15 while microvascular dysfunction will be defined by an Index of Microcirculatory Resistance (IMR) of ≥25.16 Patients will undergo study-related clinical follow up at 30 days and 12 months.

03

Conditions studied

  • Calcified Atheroma
  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than 18 years.
  • The subject has stable or unstable angina pectoris, or a positive functional study for ischemia.
  • The subject is eligible for PCI.
  • The subject gives consent prior to study inclusion.
  • The subject has a calcified lesion that does not dilated fully after balloon angioplasty at 16atm with a ≥2.5mm non-compliant balloon.
  • The calcified lesion has a 50-90% diameter stenosis by angiographic assessment.

Exclusion criteria

Exclusion Criteria:

  • Previous and/or planned brachytherapy of target vessel.
  • Pregnant and/or breast-feeding females or females who intend to become pregnant.
  • Patients who intend to have a major surgical intervention within 6 months of enrolment in the study.
  • Patients who previously participated in this study.
  • Subject has experienced an acute myocardial infarction 72 hours prior to the index procedure, as defined either by the presence of a new Q-wave in 2 or more contiguous leads, or by a CK greater than two times site upper reference limit (URL) with presence of CK-MB greater than the site URL.
  • The subject has suffered a stroke or transient ischemic neurological attack or cerebrovascular accident within the past six months, or has any known intracranial mass, arteriovenous malformation, aneurysm or other intracranial pathology.
  • The subject has experienced a significant gastrointestinal or genitourinary bleed within the past six months, or has had any active bleeding within two months.
  • Planned revascularization of target vessel within 1 year after index procedure.
  • Lesions not ideal for Shockwave treatment:
  • Longer than 40mm.
  • The target vessel contains intraluminal thrombus.
  • The subject has had a prior stent in the target lesion, including a 5mm zone proximal and distal to the lesion.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    Rotablation

    Use of rotational atherectomy first-line if NC balloon does not fully open

    Device: Rotablation of shockwave

  • Active comparator
    Shockwave IVL

    Use of Shockwave IVLS first-line if NC balloon does not fully open

    Device: Rotablation of shockwave

Interventions

  • DeviceRotablation of shockwave

    Patients will be randomized to treatment with rotablation or shockwave

06

What researchers measure

Primary outcomes

  1. Difference in peri-procedural myocardial infarction (Type 4a)

    Measurements of HS Troponine T at 8hrs, 16hrs and 24 hrs post PCI

    Time frame: within 24 hours of index PCI

Secondary outcomes

  1. Procedural differences (technical and procedural success, procedural characteristics and costs).

    procedural characteristics

    Time frame: periprocedural

  2. Difference in change in IMR between the two groups.

    measurement of IMR before and after PCI

    Time frame: periprocedural

  3. Clinical outcomes at 30-days and 1 year.

    clinical outcomes (Major adverse clinical events, including MI, TLR and cardiac death)

    Time frame: 1 year

  4. IMR change post-PCI in calcified lesions

    measurement of IMR before and after PCI

    Time frame: periprocedural

  5. Peri-procedural myocardial injury incidence

    Measurements of HS Troponine T at 8hrs, 16hrs and 24 hrs post PCI

    Time frame: periprocedural

07

Study locations

1 of 1 sites recruiting
  • University Hopsitals Leuven
    Leuven, Brabant 3000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2025, 34 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 34 months is close to that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Jan 26, 2022
StartActual
Feb 4, 2022
Primary completionEst.
Jan 1, 2025
CompletionEst.
Jan 1, 2025
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05208749
Collaborators
Ziekenhuis Oost-Limburg, University Hospital, Ghent, Universitair Ziekenhuis Brussel, Ziekenhuis Netwerk Antwerpen (ZNA), Imelda Hospital, Bonheiden, AZ Sint-Lucas Brugge, Centre Hospitalier Universitaire Saint Pierre, Hôpital Jolimont
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Feb 4, 2022
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Jul 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion